Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015;4(6):381-6.
doi: 10.2217/cns.15.30. Epub 2015 Oct 26.

Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients

Emilie Le Rhun  1   2   3 , Marc C Chamberlain  4 , Fahed Zairi  3   5 , Christine Delmaire  6 , Ahmed Idbaih  7   8 , Florence Renaud  9   10   11 , Claude Alain Maurage  9   10   11 , Valérie Grégoire  9   10   11
Affiliations
Case Reports

Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients

Emilie Le Rhun et al. CNS Oncol. 2015.

Abstract

Two patients with an unmethylated MGMT promoter and IDH1 (R132H) wild-type recurrent glioblastoma were treated with crizotinib. Prolonged stabilization of the disease (17 months) was achieved in the first case. Interestingly, anaplastic lymphoma kinase (ALK) expression and c-MET protein overexpression was observed. Conversely, no response to crizotinib was obtained in the second case with MET protein overexpression and c-MET amplification but no ALK expression or ALK gene amplification. These case studies suggest that novel targeted ALK inhibitors may provide relevant clinical benefit in selected cases in which driver mutations are demonstrable.

Keywords: ALK; MET; MET amplification; crizotinib; glioblastoma; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Coronal T1 enhanced brain MRI during the follow-up of the patient.
<b>Figure 2.</b>
Figure 2.. ROS1, ALK, c-MET immunohistochemical and FISH analysis for the first patient.
<b>Figure 3.</b>
Figure 3.. ROS1, ALK, c-MET immunohistochemical and FISH analysis for the second patient.
See this image and copyright information in PMC

References

    1. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma – are we there yet? Neuro Oncol. 2013;15(1):4–27. - PMC - PubMed
    1. Le Rhun E, Rhun EL, Taillibert S, Chamberlain MC. The future of high-grade glioma: where we are and where are we going. Surg. Neurol. Int. 2015;6(Suppl. 1):S9–S44. - PMC - PubMed
    1. Liu W, Fu Y, Xu S, et al. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme. J. Clin. Neurosci. 2011;18(1):119–121. - PubMed
    1. Wallace GC, 4th, Dixon-Mah YN, Vandergrift WA, 3rd, et al. Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. Metab. Brain Dis. 2013;28(3):355–366. - PMC - PubMed
    1. Mesaros EF, Ott GR, Dorsey BD. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review. Expert Opin. Ther. Pat. 2014;24(4):417–442. - PubMed

    2. • A review on the ALK inhibitors as therapeutic option.

Publication types

MeSH terms